Evidence map›Paper›PMID 42079931›Full record

Trial reportJTCVS open2026

Outcomes of Thoracic Surgical Oncology Group 103: Multimodality management in risk-stratified patients with lung-limited metastatic colorectal cancer.

Mara B Antonoff, Zamaan Hooda, Xiaowen Sun, May Celestino, Nathaniel Evans, Tyler Grenda, Jack Lee, Reza Mehran, Olugbenga T Okusanya, Ravi Rajaram and 6 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Mara B AntonoffDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Tex.
Zamaan HoodaDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Tex.
Xiaowen SunDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Tex.
May CelestinoDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Tex.
Nathaniel EvansDepartment of Thoracic and Esophageal Surgery, Thomas Jefferson University, Philadelphia, Pa.
Tyler GrendaDepartment of Thoracic and Esophageal Surgery, Thomas Jefferson University, Philadelphia, Pa.
Jack LeeDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Tex.
Reza MehranDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Tex.
Olugbenga T OkusanyaDepartment of Thoracic and Esophageal Surgery, Thomas Jefferson University, Philadelphia, Pa.
Ravi RajaramDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Tex.
Thomas WaddellDepartment of Thoracic Surgery, University Health Network Toronto General Hospital, Toronto, Ontario, Canada.
Garrett WalshDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Tex.
Jonathan YeungDepartment of Thoracic Surgery, University Health Network Toronto General Hospital, Toronto, Ontario, Canada.
Ara VaporciyanDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Tex.
Kyle G MitchellDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Tex.
Van K MorrisDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Tex.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Thoracic Surgery Oncology Group 103 was a prospective multi-institutional trial that aimed to (1) evaluate the role of perioperative chemotherapy for low-risk patients with metastatic colorectal cancer undergoing pulmonary metastasectomy and (2) characterize the impact of surgery on outcomes for high-risk patients with metastatic colorectal cancer receiving chemotherapy. Methods: From July 2018 to September 2023, patients with histologically confirmed primary colorectal cancer and lung metastases amenable to complete margin-negative resection from 3 institutions were enrolled and stratified by low- and high-risk clinical features and randomized accordingly within 2 treatment paradigms. Results: A total of 22 and 26 patients were enrolled in the low- and high-risk cohorts, respectively. Randomization within the low-risk cohort resulted in 8 individuals (40.0%) receiving perioperative chemotherapy and surgery (+Chemo) and 12 patients (60.0%) undergoing surgery alone (-Chemo). Median overall survival was unable to be calculated for either group, and median recurrence-free survival was 21.8 months for +Chemo and not yet reached for -Chemo ( Conclusions: Patient accrual targets were not reached, leaving this study underpowered; as such, all analyses are descriptive and hypothesis generating. We were unable to determine differences in survival in the high-risk cohort; however, our findings suggest that adequately selected low-risk individuals can be treated with up-front pulmonary metastasectomy without additional lung-directed chemotherapy.

Indexed as

colorectal carcinomamultimodality therapypulmonary metastasectomypulmonary metastasesrandomized clinical trial

Identifiers

PMID42079931
PMCPMC13131173

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.